Auto-Commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

Lucie de Beauchamp; Pablo Baquero; Elodie M. Kuntz; Eyal Gottlieb; G. Vignir Helgason

doi:10.1080/23723556.2017.1403532

Auto-Commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

Lucie de Beauchamp, Pablo Baquero, Elodie M. Kuntz, Eyal Gottlieb, G. Vignir Helgason

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Abstract

We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

Original language	English (US)
Article number	e1403532
Journal	Molecular and Cellular Oncology
Volume	5
Issue number	1
DOIs	https://doi.org/10.1080/23723556.2017.1403532
State	Published - Jan 2 2018
Externally published	Yes

Keywords

CML
Cancer stem cells
Cancer stem cells
Imatinib
Leukaemia
Metabolism
OXPHOS
TCA cycle
Tigecycline
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Molecular Medicine
Cancer Research

Access to Document

10.1080/23723556.2017.1403532

Cite this

@article{8167a5241b6f4d59ac14f764f9225dfb,

title = "Auto-Commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”",

abstract = "We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.",

keywords = "CML, Cancer stem cells, Cancer stem cells, Imatinib, Leukaemia, Metabolism, OXPHOS, TCA cycle, Tigecycline, Tyrosine kinase inhibitor",

author = "{de Beauchamp}, Lucie and Pablo Baquero and Kuntz, {Elodie M.} and Eyal Gottlieb and Helgason, {G. Vignir}",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2018",

month = jan,

day = "2",

doi = "10.1080/23723556.2017.1403532",

language = "English (US)",

volume = "5",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Auto-Commentary on

T2 - “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

AU - de Beauchamp, Lucie

AU - Baquero, Pablo

AU - Kuntz, Elodie M.

AU - Gottlieb, Eyal

AU - Helgason, G. Vignir

PY - 2018/1/2

Y1 - 2018/1/2

N2 - We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

AB - We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

KW - CML

KW - Cancer stem cells

KW - Imatinib

KW - Leukaemia

KW - Metabolism

KW - OXPHOS

KW - TCA cycle

KW - Tigecycline

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85050757018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050757018&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1403532

DO - 10.1080/23723556.2017.1403532

M3 - Comment/debate

C2 - 29404396

AN - SCOPUS:85050757018

SN - 2372-3556

VL - 5

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 1

M1 - e1403532

ER -

Auto-Commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this